This page includes information on:
The Journal of Haemophilia Practice accepts papers from all members of the multidisciplinary bleeding disorders care team, as well as outcomes research written by and/or with people affected by bleeding disorders.
We positively welcome the submission of any manuscript that is relevant to current haemophilia practice, including:
- Original research
- Case reports
- Case series
- Methodology papers
- Reviews in any field of bleeding disorders relevant to current practice
- Clinical updates describing current advances in any clinical field relating to bleeding disorders
- Opinion pieces and editorials that address a particular topic of current interest.
Although we do not specify wordcounts for articles, we recommend the following:
- For shorter papers, e.g. case reports and small cohort studies: 1,000–3,000 words
- For reviews, larger studies and qualitative studies, which require explanation of methodologies: 3,000–7,000 words.
The journal does not charge submission fees, but articles accepted for publication are subject to article processing charges (APCs) from 1 January 2024. APC waivers are available in some circumstances. Please see ‘Fees and funding’ in our Editorial Polices and Publication Ethics.
Title should be short and informative. For case reports, the words ‘case report’ should be included in the title.
Full author names and affiliation should be given.
Authorship should be based on the following four criteria:
- Substantial contributions to the conception or design of the work AND
- Drafting the work or revising it critically for important intellectual content AND
- Final approval of the version to be published; AND
- Agreement to be accountable for all aspects of the work in its entirety.
The corresponding author takes primary responsibility for communication with the journal during the manuscript submission, peer review, and publication process, and typically ensures that all the journal’s administrative requirements, such as providing details of authorship, ethics committee approval, clinical trial registration documentation, and gathering conflict of interest forms and statements, are properly completed, although these duties may be delegated to one or more co-authors.
ORCID details for each author should be provided where available. ORCID is a not-for-profit global registry that provides individual authors and researchers with a unique, persistent identifier. Embedding ORCID iDs enables the linking of an individual’s professional activities and publications, ensuring proper attribution and disambiguation. Registration is free.
For original articles, a short abstract should be provided using the following headings: Background or Introduction, Aims, Methods, Results, Conclusion.
Submissions should include 3–6 keywords for indexing purposes.
Manuscripts accepted for publication will be published in UK English.
Avoid the use of the word ‘patient’ or ‘patients’ where possible. Preferred alternatives include ‘person/people with haemophilia (PwH)’, ‘person/people with (a) bleeding disorder’, etc.
Generic drug names should be used in text, tables and figures.
Suppliers of drugs, equipment and other brand-name material should be credited in parentheses (company, brand name, city, state, country).
Figures and tables
Figures and tables should be supplied in a separate document (or documents). Any data underlying charts and graphs should be provided.
Journal titles should be abbreviated according to the style of Index Medicus and spelled out in full if not listed in Index Medicus.
The DOI (digital object identifier) associated with journal articles should be provided where available.
Where there are six or more authors associated with a reference, the first three should be listed, followed by ‘et al.’
Reference style examples:
- Reference to an article:
Khair K, Klukowska A, Myrin Westesson L, et al. The burden of bleeds and other clinical determinants on caregivers of children with haemophilia (the BBC Study). Haemophilia 2019; 25(3): 416-423. doi: 10.1111/hae.13736.
- Reference to a book:
Jones P. Living with Haemophilia. 2002. Oxford: Oxford University Press.
- Reference to a chapter in a book:
Escobar MA, Roberts HR. Less common congenital disorders of hemostasis. In: Kitchens CS, ed. Consultative Hemostasis and Thrombosis, 3rd edn. 2013. Philadelphia, PA: W.B. Saunders Company.
- Reference to a webpage/online resource:
European Medicines Agency (EMA). European Public Assessment Report (EPAR) NovoSeven Summary for the Public. 2009. Available from http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000074/human_med_000936.jsp&mid=WC0b01ac058001d124 (accessed 9 September 2013).
Where appropriate, The Journal of Haemophilia Practice supports the sharing of data that supports the research in published articles. Authors are encouraged to include a statement on the availability of research data in submitted manuscripts.
All funding sources should be listed in the manuscript’s Acknowledgements section.
For manuscripts describing studies involving human participants, authors should confirm that informed consent was obtained from those involved and described how this was obtained.
Identifying information, including names, initials, dates of birth or hospital numbers, should not be published in written descriptions, photographs or pedigrees unless the information is essential for scientific purposes and the person (or parent or guardian) gives written informed consent for publication.
See also: Resources
Submitting a manuscript
All manuscripts should be submitted via The Journal of Haemophilia Practice’s ScholarOne submissions portal.
You will need to log in. If you are using Scholar One for the first time, use the ‘Create an Account’ link.
Once you have logged in, select the ‘Author’ tab and follow the on-screen instructions – the system will guide you through the process of manuscript submission. Alongside the manuscript, accompanying figures and tables, and general information about the manuscript, you will be asked to provide:
- The names of suggested reviewers (optional)
- A cover letter signed on behalf of all co-authors by the corresponding author
- An open access license agreement, completed by the corresponding author on behalf of all co-authors
- Details of any conflicts of interest
- Confirmation that informed consent has been obtained where appropriate
- Confirmation of whether you wish to request a waiver for article processing charges (see ‘Fees and funding’ in the journal’s Editorial Policies and Publication Ethics).
After submitting your manuscript, you will receive a confirmation email.
You can check on the status of your manuscript at any time by logging in to your Scholar One account.
The journal editors will notify you by email when a decision has been made on your manuscript.
All manuscripts submitted to The Journal of Haemophilia Practice are first subject to a technical review. This includes a quality check of all files submitted, including tables, figures, and references, and a plagiarism check. Manuscripts are then reviewed by the editor-in-chief, who decides whether or not to proceed to peer review. The editor-in-chief may recommend immediate revision prior to review for manuscripts where there are issues with language (writing support is available).
Peer review is managed within the journal’s ScholarOne portal. Independent experts, researchers and members of the Editorial Board are invited to critically review manuscripts for originality, validity and significance, which helps the editors in decision-making on whether or not to publish. Authors may suggest peer reviewers at the time of manuscript submission.
Manuscripts are usually assessed by two peer reviewers in addition to The Journal of Haemophilia Practice’s Editor-in-Chief. All peer reviews are conducted on a ‘double blind’ basis, meaning that the identities of authors are not disclosed to reviewers and the identities of reviewers are not disclosed to authors. The review process will result in one of four decisions: Accept, Major Revision, Minor Revision, or Reject. This decision, along with feedback from the peer reviewers, will be communicated to the authors at the earliest opportunity. We generally aim to complete the peer review process within six weeks, but delays are sometimes unavoidable.
In practice, manuscripts are rarely accepted in their original form. Where the peer review decision requires the submission of a revised manuscript (with either major or minor revisions), this should be returned with a response to points raised in the reviewer feedback. The revised manuscript will be assessed again by the editorial team and may be sent to back to the reviewers for decision on a new recommendation. The final decision rests with the editor-in-chief.
In cases where major revisions are advised or the recommendation is to reject, The Journal of Haemophilia Practice has a policy of working with authors to improve manuscripts (see Writing support).
If you believe an error has been made in reaching a decision about your manuscript, please address your concerns to the Editor in the first instance: email email@example.com. Your appeal should include a detailed statement justifying why you think a mistake has been made and how you intend to address specific criticisms raised by peer reviewers or members of the editorial team during the review process. Appeal decisions will be made by the Editor-in-Chief in liaison with members of the editorial team and/or the journal’s Editorial Board as appropriate. After receipt of an appeal, we will aim to advise on whether your manuscript will be reconsidered within two weeks.
The Journal of Haemophilia Practice has a policy of supporting authors who are non-native English speakers, those who are not skilled writers, and those who are new to academic writing. This includes:
- Support for authors to revise manuscripts identified by the editor-in-chief as in need of immediate revision prior to peer review
- Support for authors to revise manuscripts identified in peer review as not yet suitable for publication but where the reviewers or the editor-in-chief believe the subject matter to be of merit.
Once a manuscript is accepted for publication, the corresponding author (or their institution or funder) will be invoiced for article processing charges (APCs). Manuscripts accepted for publication will not be published until APC payment is settled (unless a waiver was agreed when the manuscript was submitted). See ‘Fees and funding’ in the journal’s Editorial Policies and Publication Ethics.
All manuscripts accepted for publication are proofed and copy edited by the journal’s editorial team. Our in-house editors will work with authors to ensure that all published articles are accurate, and that the language used is clear.
The following are routinely added to all manuscripts during preparation for publication:
- Digital object identifier/DOI (to provide persistent link to the article)
- A statement confirming Open Access licensing
- An image (stock or supplied by authors) with article summary caption
- Acknowledgements section confirming any interests posing potential author conflict or bias, and a statement relating to informed consent
- Author ORCID details
- Citation information.
Authors will receive email notification with a link to the journal’s ScholarOne portal when a PDF proof is available. This should be carefully checked to ensure that all data is correct and that the text is accurate. Online guidance is provided within the system.
On confirmation of the proof, authors should provide a short summary (ca. 30-40 words) that can be used to promote the published article on The Journal of Haemophilia Practice’s social media channels.
The estimated time from acceptance of a manuscript to proof stage is two weeks.
The Journal of Haemophilia Practice publishes online continuously throughout the year. Once proofs are finalised, we aim to publish articles within two to three weeks.
Authors will receive an email notifying them when their article is available online.
Inclusivity is a core value of Haemnet, which owns and manages The Journal of Haemophilia Practice. Supporting unskilled or new authors to establish their publishing credentials and share their knowledge and experience clearly and effectively ultimately enables the publication of a wider range of manuscripts on a broader spectrum of topics, thereby increasing understanding among health care professionals and benefitting the care of people with bleeding disorders.
Writing a case report
Case reports and small series, presenting real-world, practice-based evidence, are important to the understanding of rare diseases such as bleeding disorders and provide a valuable source of learning. A lack of relevant educational case reports was previously identified as problematic for allied health care providers working in bleeding disorder care and is one of the reasons why The Journal of Haemophilia Practice was established.
The journal has adopted the CARE Case Report Guidelines through which we aim to ensure the accuracy, transparency and usefulness of the case reports we publish. We recommend that authors writing a case report consult the CARE Checklist of information to include.
We welcome the submission of case reports from both experienced authors and those writing up cases for the first time.
Our guide, Writing a case report, outlines the basics with reference to the CARE Guidelines.
See also: ‘We’re on the case’ on the Haemnet blog
Writing an editorial
An editorial is an opinion-based article discussing a topical issue which may seek to change other people’s opinions and is often supported with facts.
Everyone who works in bleeding disorders care will have opinions and The Journal of Haemophilia Practice welcomes editorials, particularly where they have relevance to the articles that we publish. We also understand that few people working in bleeding disorders care are regular editorial writers.
Our short guide, Writing an editorial, is intended to help those submitting clinically oriented, opinion-based articles to the journal.